3,5-二甲基异噁唑-4-羧酸 | 2510-36-3

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3,5-二甲基异噁唑-4-羧酸
• 中文别名: 3,5-二甲基异恶唑-4-甲酸；3,5-二甲基异噁唑-4-甲酸；3,5-二甲基异恶唑-4-羧酸；3,5-二甲基异?唑-4-羧酸
• 英文名称: 3,5-dimethyl-4-isoxazolecarboxylic acid
• 英文别名: 3,5-dimethyl-isoxazole-4-carboxylic acid；3,5-Dimethyl-isoxazol-4-carbonsaeure；3,5-dimethyl-isoxazol-carbonsaeure-(4)；3,5-Dimethylisoxazole-4-carboxylic acid；3,5-dimethyl-1,2-oxazole-4-carboxylic acid
• CAS: 2510-36-3
• 化学式: C₆H₇NO₃
• mdl: MFCD00051657
• 分子量: 141.126
• InChiKey: IJEUISLJVBUNRE-UHFFFAOYSA-N

物化性质

• 熔点：
  141-145 °C(lit.)
• 沸点：
  258.14°C (rough estimate)
• 密度：
  1.3710 (rough estimate)
• 溶解度：
  溶于甲醇
• 稳定性/保质期：
  在常温常压下保持稳定，应避免与氧化剂、酸、酸性氧化物及酸酐接触。

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  63.3
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 危险类别码：
  R20/21/22
• WGK Germany：
  3
• 海关编码：
  2934999090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H315,H317,H319
• 储存条件：
  请将容器密封，并存放在干燥、阴凉处。

SDS

Name:	3 5-Dimethylisoxazole-4-carboxylic acid Material Safety Data Sheet
Synonym:	None Known
CAS:	2510-36-3

Section 1 - Chemical Product MSDS Name:3 5-Dimethylisoxazole-4-carboxylic acid Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
2510-36-3	3,5-Dimethylisoxazole-4-carboxylic aci	98	219-724-5

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid.
Skin:
In case of contact, flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical aid if irritation develops and persists. Wash clothing before reuse.
Ingestion:
If swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 2510-36-3: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: light beige
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 140 - 142 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H7NO3
Molecular Weight: 141.0539

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Acids, acid chlorides, acid anhydrides, oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 2510-36-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3,5-Dimethylisoxazole-4-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 2510-36-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 2510-36-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 2510-36-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3,5-二甲基异噁唑-4-羧酸 在 盐酸 、 正丁基锂 、 碳酸氢钠 、 lithium tri-t-butoxyaluminum hydride 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙醚 、 二氯甲烷 、 水 、 甲苯 为溶剂， 反应 77.0h， 生成 tert-butyl (4S,6S)-4-(5-bromo-2,4-difluorophenyl)-6-(3,5-dimethylisoxazol-4-yl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-ylcarbamate
  参考文献：
  名称：

  Targeting the BACE1 Active Site Flap Leads to a Potent Inhibitor That Elicits Robust Brain Aβ Reduction in Rodents

  摘要：

  By targeting the flap backbone of the BACE1 active site, we discovered 6-dimethylisoxazole-substituted biaryl aminothiazine 18 with 34-fold improved BACE1 inhibitory activity over the lead compound 1. The cocrystal structure of 18 bound to the active site indicated two hydrogen-bond interactions between the dimethylisoxazole and threonine 72 and glutamine 73 of the flap. Incorporation of the dimethylisoxazole substitution onto the related aminothiazine carboxamide series led to pyrazine-carboxamide 26 as a very potent BACE1 inhibitor (IC50 < 1 nM). This compound demonstrated robust brain A beta reduction in rat dose-response studies. Thus, compound 26 may be useful in testing the amyloid hypothesis of Alzheimer's disease.

  DOI：

  10.1021/acsmedchemlett.5b00432
• 作为产物：
  描述：

  3,5-二甲基异噁唑-4-甲酸乙脂 在 sodium hydroxide 作用下， 生成 3,5-二甲基异噁唑-4-羧酸
  参考文献：
  名称：

  Claisen, Justus Liebigs Annalen der Chemie, 1893, vol. 277, p. 174

  摘要：

  DOI：

文献信息

• Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors
  申请人：John Varghese

  公开号：US20060014737A1

  公开（公告）日：2006-01-19

  The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

  这项发明涉及新型化合物和治疗与淀粉样变性相关的疾病、紊乱和症状的方法。淀粉样变性指与A-beta蛋白异常沉积相关的一系列疾病、紊乱和症状。
• [EN] MODULATORS OF THE INTEGRATED STRESS PATHWAY<br/>[FR] MODULATEURS DE LA VOIE DE RÉPONSE INTÉGRÉE AU STRESS
  申请人：CALICO LIFE SCIENCES

  公开号：WO2017193063A1

  公开（公告）日：2017-11-09

  Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

  本文提供了用于调节综合应激反应（ISR）并治疗相关疾病、疾患和症状的化合物、组合物和方法。
• Benzodiazepine and Pyridodiazepine Derivatives
  申请人：Bunnelle William H.

  公开号：US20110288069A1

  公开（公告）日：2011-11-24

  The present application relates to benzodiazepine and pyridodiazepine derivatives of formula (I) wherein R 1 , R 2 , R 3 , R 4 , X 1 , Y 1 , Y 2 , and Y 3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

  本申请涉及式(I)的苯二氮卓和吡啶二氮卓衍生物，其中R1、R2、R3、R4、X1、Y1、Y2和Y3如规范中所定义。本申请还涉及包含这类化合物的组合物，以及使用这类化合物和组合物治疗疾病症状的方法，以及识别这类化合物的方法。
• Synthesis and biological evaluation of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives as novel potent transforming growth factor-β type 1 receptor inhibitors
  作者：Guofeng Xu、Yan Zhang、Hai Wang、Zhuang Guo、Xiaowei Wang、Xue Li、Shaohua Chang、Tianwen Sun、Zhuangzhuang Yu、Tianwei Xu、Liwen Zhao、Yazhou Wang、Wenying Yu

  DOI：10.1016/j.ejmech.2020.112354

  日期：2020.7

  factor β (TGF-β) type 1 receptor (ALK5) provides a feasible approach for the treatment of fibrotic diseases and malignant tumors. In this study, we designed and synthesized a new series of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives, and evaluated biologically as TGF-β type 1 receptor inhibitors. The most potent compound 15r inhibited the ALK5 enzyme and NIH3T3 cell viability with IC50

  抑制转化生长因子β（TGF-β）1型受体（ALK5）提供了一种治疗纤维化疾病和恶性肿瘤的可行方法。在这项研究中，我们设计并合成了一系列新的4-（吡啶-4-氧基）-3-（3,3-二氟环丁基）-吡唑衍生物，并作为TGF-β1型受体抑制剂进行了生物学评估。最有效的化合物15r抑制ALK5酶和NIH3T3细胞的活力，IC50值分别为44和42.5 nM。与LY-3200882相比，化合物15r还具有更好的口服血浆暴露和出色的生物利用度，并且在CT26异种移植小鼠模型中体内抑制了65.7％的肿瘤生长。
• Synthesis and evaluation of α-aminoacyl amides as antitubercular agents effective on drug resistant tuberculosis
  作者：Vitthal B. Makane、Vagolu Siva Krishna、E. Vamshi Krishna、Manjulika Shukla、B. Mahizhaveni、Sunil Misra、Sidharth Chopra、Dharmarajan Sriram、V.N. Azger Dusthackeer、Haridas B. Rode

  DOI：10.1016/j.ejmech.2019.01.002

  日期：2019.2

  The development of an effective antitubercular agent is a challenge due to the complex nature of tuberculosis. Herein, we report the synthesis and evaluation of α-aminoacyl amides as antitubercular agents. The systematic medicinal chemistry approach led to identification of optimal substitutions required for the activity. Compound 11l was identified as antitubercular lead with drug like properties.

  由于结核病的复杂性，有效的抗结核药的开发是一个挑战。在此，我们报道了α-氨基酰胺作为抗结核药的合成和评价。系统的药物化学方法导致确定该活性所需的最佳取代。化合物11l被鉴定为具有药物样特性的抗结核药。此外，11l选择性抑制MIC值为0.78μM的结核分枝杆菌H37Rv，并且发现它对CHO K1细胞无毒。铅化合物分别以2μg/ mL和8μg/ mL抑制分枝杆菌的耐多药和广泛耐药性菌株。

表征谱图